Upside – $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%) – $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move) – $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history) …
Read in context ›Capricor Therapeutics Stock (CAPR)
Track Capricor Therapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
CAPR
Capricor Therapeutics
healthcare
At close
$7.83
â–¼ -0.18 (-2.25%)
Oct 9, 4:00 PM ET
After-hours
$7.80
â–¼ -0.03 (-0.38%)
Oct 9, 7:51 PM ET
Market Cap
$465.69M
P/E Ratio
—
1Y Return
+7.09%
EPS (TTM)
-$2.45
Read the latest TheStreet Pro articles mentioning Capricor Therapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning CAPR yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning